Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
PRINCETON, N.J., May 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) is scheduled to host a conference call and live webcast at 4:00 p.m. Eastern Time on Tuesday, June 2, 2009. Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex will provide an update and recent highlights from Medarex's pipeline.
The webcast of the live event and archive can be accessed through the Investor Relations section of Medarex's website at www.medarex.com. To access the call live, please dial 1-877-874-1567 (U.S./Canada) or 1-719-325-4768 (international).
An archived telephonic replay of the conference call will be available until midnight Eastern Time on June 9, 2009. Access numbers for this replay are 1-888-203-1112 (U.S./Canada) or 1-719-457-0820 (international); the replay passcode is 4826956.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization, or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
